Imaging software developer Median Technologies has signed a finance agreement for 35 million euros to further develop its iBiopsy imaging phenomics platform.
Median is developing noninvasive imaging biomarkers through its proprietary iBiopsy platform to help identify certain chronic disease signatures, including those for cancer. The goal is to enhance early detection, quantification of disease severity, and disease monitoring, the company said.
The funds come from the European Investment Bank, supported by the European Fund for Strategic Investments. The first distribution of 15 million euros is expected early next year, followed by allocations of 10 million euros in the coming years at Median's discretion.
The agreement involves the company repaying the financing in one installment at the end of a five-year period after the disbursement date.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
